|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the administrations of immune checkpoint modulators (represented by anti-CTLA4 and anti-PD antibodies) and adoptive immune cells (represented by CAR-T) have exhibited unexpected antitumor effect in multiple types of cancer, bringing a new era for cancer therapy.
|
31730903 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Minicircle DNA-Engineered CAR T Cells Suppressed Tumor Growth in Mice.
|
31582530 |
2020 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Efficacy and safety data for anti-CD19 CAR T-cell therapy in aggressive B-cell lymphomas will be reviewed, as well as novel CAR T-cell designs and strategies for overcoming treatment resistance.
|
31677848 |
2020 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, Igβ-specific CAR-T cells may be a promising immunotherapeutic approach for B cell lymphoma.
|
31624374 |
2020 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
|
31707682 |
2020 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The biggest advances have been made with CAR T cells and many of those studies are now FDA approved as a routine treatment for some hematologic malignancies.
|
31705854 |
2020 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the use of chimeric antigen receptor modified T (CAR-T)-cells in the treatment of hematological tumors has been successful and has become a clinical hotspot in tumor immunotherapy.
|
31790761 |
2020 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, CAR-T therapy-related severe cytokine release syndrome and neurological toxicity limit its clinical application in R/R DLBCL patients with high tumor burden.
|
31219975 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the administrations of immune checkpoint modulators (represented by anti-CTLA4 and anti-PD antibodies) and adoptive immune cells (represented by CAR-T) have exhibited unexpected antitumor effect in multiple types of cancer, bringing a new era for cancer therapy.
|
31730903 |
2020 |
|
Diffuse Large B-Cell Lymphoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates impressive efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
|
31219975 |
2020 |
|
caruncle
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to document the expression and functional role of BMPs in the placental (caruncle; CAR, cotyledon; COT) during different stages of pregnancy in water buffalo.
|
31445010 |
2020 |
|
Renal cancer metastatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
|
31574023 |
2020 |
|
Cerebellar Ataxia
|
0.160 |
Biomarker
|
phenotype |
BEFREE |
Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with <i>SPG7</i>.
|
31068484 |
2019 |
|
Cerebellar Ataxia
|
0.160 |
GeneticVariation
|
phenotype |
BEFREE |
Prevalence and phenotype of the c.1529C>T SPG7 variant in adult-onset cerebellar ataxia in Italy.
|
30098094 |
2019 |
|
Ataxia
|
0.150 |
GeneticVariation
|
phenotype |
BEFREE |
The SPG7 c.1529C>T (p.Ala510Val) mutants accounted for 2.3% of cerebellar ataxia cases in Italy, suggesting that this variant should be considered as a priority test in the presence of late-onset pure ataxia.
|
30098094 |
2019 |
|
Ataxia
|
0.150 |
Biomarker
|
phenotype |
BEFREE |
Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with <i>SPG7</i>.
|
31068484 |
2019 |
|
Muscle Spasticity
|
0.120 |
Biomarker
|
phenotype |
BEFREE |
Loss of paraplegin drives spasticity rather than ataxia in a cohort of 241 patients with <i>SPG7</i>.
|
31068484 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapy provides possibility for the treatment of malignancies since clinical trials have shown that CAR-T therapy has a significant anti-tumor effect.
|
30875561 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The adoptive transfer of chimeric antigen receptor-modified T (CAR-T) cells is a novel cancer treatment that has led to encouraging breakthroughs in the treatment of haematological malignancies.
|
31815041 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive immunotherapy based on chimeric antigen receptor-modified T (CAR-T) cells has been demonstrated as one of the most promising therapeutic strategies in the treatment of malignancies.
|
31142602 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Promising outcomes have been achieved using CAR-T cell therapy for haematological malignancies.
|
31176617 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T therapy, grafting the specificity of a monoclonal antibody onto a T cell to target certain cancer cells, has been recognized as a promising therapeutic approach for cancer control as evidenced by the two CAR-T products proved by FDA in 2017.
|
30543841 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades.
|
31190844 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells engineered with lentiviral and retroviral vectors have been successfully applied to treat patients with B cell malignancy.
|
30030293 |
2019 |